<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70389">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01770041</url>
  </required_header>
  <id_info>
    <org_study_id>12/SS/0222</org_study_id>
    <nct_id>NCT01770041</nct_id>
  </id_info>
  <brief_title>Paracetamol Metabolism After Liver Surgery</brief_title>
  <acronym>PETALS</acronym>
  <official_title>Observational Study Assessing Cytochrome P450 Dependant Paracetamol Metabolites Following Liver Resection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will assess the metabolic pathways of paracetamol that are utilised
      after liver resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paracetamol is normally metabolised by the glucuronidation and sulfation of paracetamol to
      non toxic end products. If paracetamol is administered in supra-therapeutic doses this
      pathway becomes saturated and an alternative pathway is utilised. This results in a toxic
      metabolite called N-acetyl-p-benzoquinone imine (NAPQI). If NAPQI is not metabolised by
      glutathione to cysteine and mercapturic acid, then NAPQI bind to hepatic cells resulting in
      necrosis and hepatotoxicity.

      Therefore the investigators plan to measure the levels of the paracetamol metabolites in
      patient undergoing liver resection.

      Patients will undergo liver resection according to their onco-surgical requirements. As part
      of the normal post operative care they will receive 1g paracetamol every six hours unless
      stated otherwise by the operating surgeon. Urinary samples will be taken for the first 4
      post operative days and used for analysis of the urinary paracetamol metabolite levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Urinary cysteine</measure>
    <time_frame>Post operative days 1-4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>mercapturic acid</measure>
    <time_frame>post operative days 1-4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione</measure>
    <time_frame>day of surgery and post operative days 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol level</measure>
    <time_frame>day of surgery and post operative days 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Glucuronamide</measure>
    <time_frame>Post-operative days 1-4</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Sulphate</measure>
    <time_frame>Post-operative days 1-4</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>5-oxoproline</measure>
    <time_frame>Post-operative days 1-4</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Complications</measure>
    <time_frame>Day of surgery and post-operative days 1-30</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Post-operative blood tests (FBC, U&amp;E, LFTs, Coag)</measure>
    <time_frame>Post-operative dyas 1-7</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver Resection</condition>
  <condition>Paracetamol Administration</condition>
  <arm_group>
    <arm_group_label>Liver resection group</arm_group_label>
    <description>Patients undergoing liver resection and receiving paracetamol (observation of routine administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paracetamol (observation of routine administration)</intervention_name>
    <description>Normal administration of paracetamol as prescribed by operating surgeon</description>
    <arm_group_label>Liver resection group</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with benign or malignant liver tumours that have been deemed by the hepatobiliary
        multi-disciplinary team meetiong as requiring surgical intervention.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing liver surgery

        Exclusion Criteria:

          -  Contra-indication to paracetamol

          -  Inability to give written, informed consent.

          -  Jaundice (Bilirubin &gt; 100 Î¼mol/L).

          -  Liver resection combined with secondary surgical procedure.

          -  Age &lt; 18 years.

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Hughes, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Hughes, MBChB</last_name>
    <phone>+44 131 242 3631</phone>
    <phone_ext>23631</phone_ext>
    <email>michaelh@doctors.net.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Hughes, MBChB</last_name>
      <phone>+44 131 242 3631</phone>
      <phone_ext>23631</phone_ext>
      <email>michaelh@doctors.net.uk</email>
    </contact>
    <investigator>
      <last_name>Michael J Hughes, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
